Aurora Cannabis Inc

Aurora Cannabis Inc (NASDAQ: ACB) is a Canada-based medical cannabis company primarily engaged in the cultivation, distribution, and sale of cannabis and cannabis-derived products across Canada and international markets. The Company operates through two main segments: Cannabis and Plant Propagation.

Macro Event: Proposed US Cannabis Rescheduling Sparks Broad-Based Rally Across North American Cannabis Stocks

The sharp rally in U.S. and Canadian cannabis stocks on Friday, reflects growing investor confidence in a potentially transformative regulatory shift, as the anticipated reclassification of marijuana from Schedule I to Schedule III under the U.S. Controlled Substances Act would formally acknowledge its medical use and materially reduce long-standing legal and financial constraints on the industry. The most significant impact would be the effective removal of IRC Section 280E, enabling state-legal cannabis operators to deduct normal business expenses and sharply improve profitability, cash flows, and balance-sheet strength. In parallel, rescheduling could ease access to traditional banking services, lower financing costs, and broaden institutional participation by reducing federal legal risk. Canadian cannabis companies also rallied strongly, driven by expectations that U.S. regulatory easing would open pathways to the world’s largest cannabis market through partnerships, acquisitions, or direct entry. Overall, the move represents a major regulatory de-risking event that has prompted a rapid re-rating of the sector, underpinned by improved long-term earnings visibility rather than immediate demand changes.

Key Business Updates:

• Record Medical Cannabis Revenue and Profitability Focus: Aurora Cannabis Inc. reported a strong financial performance for the second quarter of fiscal 2026, underscoring its strategic focus on profitable growth within the global medical cannabis segment. Global medical cannabis net revenue increased 15% year over year to a record CAD 70.5 million, while consolidated net revenue rose 11% to CAD 90.4 million. This performance reflects the Company’s continued prioritisation of higher-margin medical cannabis markets over lower-margin consumer segments.
• International Expansion and Market Leadership: International medical cannabis revenue increased 22% year over year to a record CAD 42.7 million, driven by higher sales volumes across Australia, Germany, Poland, and the United Kingdom. Aurora maintained its leading position in Canada and strengthened its presence in key international medical cannabis markets, supported by its regulatory expertise, global distribution network, and GMP-certified manufacturing capabilities. Increased sales to both insurance-covered and self-paying patients further contributed to revenue growth in the domestic market.
• Margin Expansion and Operational Efficiency: Consolidated adjusted gross margin before fair value adjustments improved to 61% in Q2 FY2026 from 54% in the prior-year period, while adjusted gross profit increased 22% to CAD 51.8 million. Medical cannabis continued to be the primary earnings driver, accounting for 94% of adjusted gross profit, with segment margins improving to 69%. Margin expansion was supported by sustainable cost reductions, higher average selling prices, and improved production efficiency, including increased sourcing of European demand from Canadian facilities.
• Segment Performance Overview: Medical cannabis remained the core contributor to performance, representing 78% of consolidated net revenue. Consumer cannabis revenue declined 34% year over year to CAD 6.9 million, reflecting the Company’s deliberate strategy to allocate GMP-manufactured supply toward higher-margin medical channels. Despite lower revenue, consumer cannabis margins improved to 27% due to cost efficiencies. Plant propagation revenue, driven entirely by the Bevo business, increased 34% year over year to CAD 11.6 million, supported by organic growth and expanded capacity, although margins declined due to non-recurring inventory write-offs and surplus crop costs.
• Cost Structure and Earnings Performance: Adjusted selling, general, and administrative expenses increased 12% year over year to CAD 35.5 million, primarily due to higher freight and logistics costs associated with increased European exports and incremental expenses following the MedReleaf Australia acquisition. Adjusted net income more than doubled to CAD 7.1 million, while adjusted EBITDA rose 52% year over year to CAD 15.4 million, reflecting strong operating leverage from higher medical cannabis volumes and sustained margin strength.
• Balance Sheet Strength and Cash Position: Aurora maintained a strong balance sheet, supported by CAD 141.9 million in cash and a debt-free cannabis business, excluding non-recourse debt related to the Bevo Farms subsidiary. Working capital remained robust at CAD 299.7 million, providing significant financial flexibility. The Company’s solid liquidity position underpins its ability to support ongoing international expansion, operational investments, and near-term growth initiatives.
• Outlook and Near-Term Expectations: Looking ahead to the third quarter of fiscal 2026, Aurora expects consolidated net revenue to increase year over year, driven by 8% to 12% growth in the global medical cannabis segment. Adjusted gross margins are expected to remain strong, supported by industry-leading cannabis margins, while plant propagation revenue is anticipated to follow normal seasonal patterns. Continued revenue growth and margin discipline are expected to translate into year-over-year adjusted EBITDA growth and positive free cash flow in Q3 FY2026.

Technical Observation (on the daily chart):

The stock has staged a strong short-term rebound, closing around USD 5.40 and breaking above its 20-day and 50-day moving averages, which signals improving trend strength. Momentum is elevated, with RSI in overbought territory, reflecting aggressive buying but also implying the potential for near-term consolidation.

Aurora Cannabis Inc. is positioning itself as a medical-led cannabis operator with improving profitability and a stronger balance sheet. The company is benefiting from a supportive macro backdrop, as proposed U.S. cannabis rescheduling has triggered a broad re-rating of North American cannabis stocks by easing long-term regulatory and tax overhangs. Operationally, Aurora’s record global medical cannabis revenue, double-digit international growth, and expanding gross margins highlight a deliberate shift toward higher-margin medical markets and away from commoditised recreational sales. Segment performance is increasingly diversified through its Bevo plant propagation business and disciplined cost management, driving meaningful EBITDA and net income improvement. With a debt-free cannabis segment, solid cash reserves, and guidance for continued revenue growth and margin resilience into FY2026, Aurora appears well placed to capitalise on regulatory catalysts and medical demand growth. As per the above-rationale price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given to Aurora Cannabis Inc (NASDAQ: ACB) at the closing market price of USD 5.40, as of Dec 12,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is Dec 12,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.